BioSpace News Archive

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has closed the sale of 3,362,833 Units at a subscription price of $0.12 per Unit for gross proceeds of $403,539.96.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), is pleased to announce that PreveCeutical is furthering the progress of two of its patent families.

The Alberta Cancer Foundation, Alberta Health Services and the University of Calgary are thrilled to announce a historic and transformational $50 million donation to the Calgary Cancer Centre from the Arthur J.E. Child Foundation.

ANGLE plc, a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier , all resolutions were duly passed.

San Francisco, California--(Newsfile Corp. - June 28, 2023) - In an industry-first, Phizzle, Inc. is now the only company to digitize the five scientific instruments that are the everyday “workhorses” of drug development and production.

NeuBase Therapeutics, Inc. announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 578,697 of its shares of common stock in a registered direct offering at a purchase price of $2.57 per share and associated unregistered warrants.

AusperBio Therapeutic, Inc. and Ausper Biopharma Co., Ltd. (Together AusperBio), a clinical-stage biotech company announced that the Center for Drug Evaluation (CDE) of China has approved the Investigational New Drug (IND) application of AHB-137 to treat chronic hepatitis B (CHB) aiming for functional cure.

IdentifySensors® Biologics, a leading developer of digital diagnostic technologies, announces the formation of the company’s new Clinical Studies Group, responsible for testing new diagnostic devices in preparation for FDA submissions.

Integra LifeSciences Holding Corporation, a leading global medical technology company, announced the completion of patient enrollment in the DuraSorb U.S. investigational device exemption clinical study for two-stage breast reconstruction.

PAVmed Inc. announced that it received a written notice from the Nasdaq Stock Market LLC granting the Company a 180-day extension to regain compliance with Nasdaq’s $1.00 minimum bid price requirement as set forth in Nasdaq Listing Rule 5550.